Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edward Paule who wrote (5094)	12/11/1997 3:13:00 PM
From: aknahow	Respond to of 17367

Canceled my order to sell puts which for some strange reason did not get tripped these last two days and put in limit order for some XOMA. The puts were on a biotech co but I was also looking at selling puts on three computer teck cos for weeks now. Indeed I feel more comfortable with Xoma even though I don't need any more. People on the tech treads think the fabs in asia will have to buy the curent technology to stay in the game. Will they make the right decision? Will they have the funds to buy? Who says they won't delay? Big risk in biotech but still like this area better and feel comfortable with XOMA.

To: Edward Paule who wrote (5094)	12/11/1997 5:08:00 PM
From: aknahow	Respond to of 17367

Ed, I did not do you justice in my post. Like you care, but put in my order after seeing your post. Had about 1 hr to go and did not get it. Note that Cramer at The Street is saying tech is still dead but that drugs are one alternative. He did not say biotech, just the broader -DRUGS. BTW, Celeryroot who used to post here got mentioned by F. J. Abella (sp) on the Westerguard site. I used to think I did not like J. Westerguard and by association Abella. Now, I believe info is info. Abella in defending himself against being a paid shill points out he does say negative things about cos that pay for coverage. But his main point is that it is the underwriters that are really the paid shills and the public seldom remembers that the analyst at a firm that was the underwriter have a tough time saying sell.